At the news
? MIXEDIMPACT 5/10 8-K filed Mar 5, 2026 at 16:08 ET
Caribou Biosciences reported its 2025 financial results, showing a slight improvement in net loss despite a $21.3M non-cash impairment charge. The company highlighted positive clinical data for its allogeneic CAR-T therapies vispa-cel and CB-011, with longer-term data expected in 2026. Cash reserves decreased to $142.8M but are expected to fund operations into 2H 2027.
- Licensing revenue increased to $11.2M in 2025 from $10.0M in 2024
- R&D expenses decreased to $109.4M in 2025 from $130.2M in 2024
- GAAP net loss was $148.1M in 2025 vs $149.1M in 2024
- Non-GAAP net loss improved to $126.8M in 2025 from $149.1M in 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access